Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP)
    1.
    发明授权
    Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP) 有权
    用BMP结合肽(BBP)增强骨形态发生蛋白(BMP)保留

    公开(公告)号:US09072709B2

    公开(公告)日:2015-07-07

    申请号:US13379436

    申请日:2010-06-23

    摘要: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.

    摘要翻译: 在美国每年进行的150万次骨移植手术中,使用自体骨移植是目前的黄金标准。 尽管这种做法导致融合率高,但与手术时间和失血量相关,伴随着供体位点发病率的显着程度。 另外,在某些情况下,例如修订案例,多层次结构,或在具有医学合并症的患者中,自体骨移植可能存在数量有限和质量上的问题。 对于自体骨移植物的合适替代物的这种显着需要刺激了对骨移植物替代物和增量剂的探索的极大兴趣。

    ENHANCEMENT OF BMP RETENTION
    2.
    发明申请
    ENHANCEMENT OF BMP RETENTION 有权
    BMP保留的增强

    公开(公告)号:US20120184490A1

    公开(公告)日:2012-07-19

    申请号:US13379436

    申请日:2010-06-23

    IPC分类号: A61K38/18 A61P19/00

    摘要: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.

    摘要翻译: 在美国每年进行的150万次骨移植手术中,使用自体骨移植是目前的黄金标准。 尽管这种做法导致融合率高,但与手术时间和失血量相关,伴随着供体位点发病率的显着程度。 另外,在某些情况下,例如修订案例,多层次结构,或在具有医学合并症的患者中,自体骨移植可能存在数量有限和质量上的问题。 对于自体骨移植物的合适替代物的这种显着需要刺激了对骨移植物替代物和增量剂的探索的极大兴趣。

    Activating Extraction Of Demineralized Bone Matrix
    8.
    发明申请
    Activating Extraction Of Demineralized Bone Matrix 有权
    激活脱钙骨基质提取

    公开(公告)号:US20080268012A1

    公开(公告)日:2008-10-30

    申请号:US11791940

    申请日:2005-11-29

    摘要: Demineralized bone matric (DBM) and native bone morphogenetic protein (nBMP) are complex mixtures of non-collagenous bone proteins. These mixtures contain many of the BMPs that are available as recombinant molecules. Information regarding the presence in these materials of molecules that may affect the availability and activity of the BMPs is very limited. A chemical extraction of DBM, such as using alkali-urea produces a water soluble extractate which inhibits the osteogenic activity of DBM. Noggin, an extracellular BMP ligand antagonist is found in the water soluble extractate from DBM. Differential chemical extraction is a useful means of removing non-osteogenic, or osteogenic inhibitory molecules from DBM and nBMP.

    摘要翻译: 脱矿骨质(DBM)和天然骨形态发生蛋白(nBMP)是非胶原性骨蛋白的复杂混合物。 这些混合物含有许多可用作重组分子的BMP。 关于可能影响BMP的可用性和活性的这些分子材料的存在的信息非常有限。 DBM的化学提取,例如使用碱 - 尿素,产生一种抑制DBM成骨活性的水溶性提取物。 在DBM的水溶性提取物中发现Noggin是细胞外BMP配体拮抗剂。 差异化学提取是从DBM和nBMP中去除非成骨或成骨抑制分子的有用手段。